# RNH1

## Overview
RNH1 is a gene that encodes the protein ribonuclease/angiogenin inhibitor 1, a leucine-rich repeat (LRR) protein known for its role in inhibiting ribonucleases such as RNase A and angiogenin. This inhibition is crucial for protecting RNA from degradation, thereby playing a significant role in cellular processes like translation and erythropoiesis (Sarangdhar2023Human; Chennupati2018Ribonuclease). The protein is characterized by its horseshoe-shaped tertiary structure, which is stabilized by leucine residues and facilitates high-affinity binding to ribonucleases (Dickson2005Ribonuclease). RNH1 is involved in various cellular functions, including the regulation of erythroid differentiation and inflammasome activation, highlighting its importance in both normal physiology and disease states (Bombaci2021LRR; Chennupati2018Ribonuclease). Mutations in the RNH1 gene have been linked to several clinical conditions, underscoring its critical role in maintaining cellular homeostasis and immune response modulation (HedbergOldfors2023Ribonuclease).

## Structure
RNH1, also known as ribonuclease/angiogenin inhibitor 1, is a protein characterized by its leucine-rich repeat (LRR) domains, which are crucial for its protein-protein interactions. The primary structure of RNH1 consists of a sequence of amino acids forming a 50 kDa protein composed of 15 LRRs (HedbergOldfors2023Ribonuclease). These repeats contribute to the secondary structure, which includes alternating α-helices and β-strands, forming a horseshoe-shaped tertiary structure (Dickson2005Ribonuclease; Chennupati2018Ribonuclease). This horseshoe shape is stabilized by leucines and other aliphatic residues, creating a hydrophobic core essential for the protein's stability and function (Dickson2005Ribonuclease).

The quaternary structure of RNH1 involves its interaction with ribonucleases, where it binds with high affinity, inhibiting their activity. This interaction is facilitated by the extensive surface area provided by the LRRs, which allows for significant protein-protein interaction (Dickson2005Ribonuclease). RNH1 also contains numerous cysteine residues, which may play structural roles and protect the protein from oxidative damage (Chennupati2018Ribonuclease). The protein's structure is crucial for its function, as mutations or deletions in specific LRRs can significantly affect its binding affinity and specificity (Lee1990Modular).

## Function
Ribonuclease inhibitor 1 (RNH1) is a protein that plays a critical role in regulating erythropoiesis by controlling the translation of the transcription factor GATA1. RNH1 is involved in the differentiation of erythroid cells by facilitating the translation of GATA1 mRNA, which is essential for erythroid maturation and enucleation. This process is crucial for maintaining normal erythropoiesis, as evidenced by decreased erythroid differentiation in RNH1-deficient cells (Chennupati2018Ribonuclease).

RNH1 is a leucine-rich repeat protein that binds to and inhibits ribonucleases, such as RNase A and angiogenin (ANG), protecting RNA from degradation. It is primarily localized in the cytosol but can also be found in the nucleus and mitochondria, indicating its involvement in various cellular processes (Dickson2005Ribonuclease; Sarangdhar2023Human).

In addition to its role in erythropoiesis, RNH1 interacts with the small ribosomal subunit, suggesting a broader role in translation. It enhances polysome formation, thereby promoting the translation of specific mRNAs, including those of key transcription factors involved in erythropoiesis (Chennupati2018Ribonuclease). This function is crucial for cellular homeostasis and the prevention of unwanted RNA degradation.

## Clinical Significance
Mutations and alterations in the RNH1 gene are associated with several clinical conditions. A homozygous splice-site variant (c.615-2A > C) in RNH1 has been linked to a disease characterized by congenital cataracts, global developmental delay, myopathy, infection-induced psychomotor regression, seizures, and macrocytic anemia. This variant leads to exon 7 skipping, resulting in a transcript lacking 57 codons and the absence of full-length RNH1 protein, effectively making patients functionally RNH1 'knockouts' (HedbergOldfors2023Ribonuclease).

RNH1 deficiency is also implicated in increased susceptibility to RNase-induced damage, particularly during infections, as shown by increased cell death in patient-derived fibroblasts treated with RNase A (Sarangdhar2023Human). In mice, RNH1 deficiency leads to embryonic lethality due to anemia, highlighting its role in erythropoiesis (Chennupati2018Ribonuclease).

Alterations in RNH1 expression are associated with inflammatory conditions. RNH1 acts as a negative regulator of the NLRP3 inflammasome, and its deficiency leads to increased inflammasome activation and inflammation. This has been linked to severe outcomes in COVID-19 patients, where decreased RNH1 expression correlates with increased disease severity (Bombaci2021LRR; Bombaci2022LRRprotein).

## Interactions
RNH1, or ribonuclease/angiogenin inhibitor 1, is known for its high-affinity binding to pancreatic-type ribonucleases, such as RNase A and angiogenin, forming stable complexes that inhibit their enzymatic activity (Dickson2005Ribonuclease). This interaction involves extensive protein-protein contacts, with the C-terminal module of RNH1 playing a crucial role in blocking the active site of RNase A (Dickson2005Ribonuclease). RNH1 also interacts with ribosomal components, specifically associating with the 40S ribosomal subunit and ribosomal proteins RPL11 and RPS3, which suggests its involvement in the translation machinery (Chennupati2018Ribonuclease). This interaction is crucial for the regulation of GATA1 translation, a key factor in erythropoiesis (Chennupati2018Ribonuclease).

RNH1's role extends to the regulation of inflammasome activation, where it mediates the degradation of caspase-1 through the proteasome, thereby inhibiting inflammasome activation (Bombaci2021LRR). This regulatory function is specific, as RNH1 does not affect the degradation of other proteases like OMI/HTRA2 (Bombaci2021LRR). These interactions highlight RNH1's multifaceted role in cellular processes, including translation regulation and immune response modulation.


## References


[1. (Chennupati2018Ribonuclease) Vijaykumar Chennupati, Diogo F.T. Veiga, Kendle M. Maslowski, Nicola Andina, Aubry Tardivel, Eric Chi-Wang Yu, Martina Stilinovic, Cedric Simillion, Michel A. Duchosal, Manfredo Quadroni, Irene Roberts, Vijay G. Sankaran, H. Robson MacDonald, Nicolas Fasel, Anne Angelillo-Scherrer, Pascal Schneider, Trang Hoang, and Ramanjaneyulu Allam. Ribonuclease inhibitor 1 regulates erythropoiesis by controlling gata1 translation. Journal of Clinical Investigation, 128(4):1597–1614, March 2018. URL: http://dx.doi.org/10.1172/jci94956, doi:10.1172/jci94956. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci94956)

[2. (Dickson2005Ribonuclease) Kimberly A. Dickson, Marcia C. Haigis, and Ronald T. Raines. Ribonuclease Inhibitor: Structure and Function, pages 349–374. Elsevier, 2005. URL: http://dx.doi.org/10.1016/s0079-6603(05)80009-1, doi:10.1016/s0079-6603(05)80009-1. This article has 167 citations.](https://doi.org/10.1016/s0079-6603(05)80009-1)

3. (Bombaci2021LRR) LRR protein RNH1 dampens the inflammasome activation and is associated with adverse clinical outcomes in COVID-19 patients. This article has 1 citations.

[4. (HedbergOldfors2023Ribonuclease) Carola Hedberg-Oldfors, Sanhita Mitra, Angela Molinaro, Kittichate Visuttijai, Linda Fogelstrand, Anders Oldfors, Fredrik H. Sterky, and Niklas Darin. Ribonuclease inhibitor 1 (rnh1) deficiency cause congenital cataracts and global developmental delay with infection-induced psychomotor regression and anemia. European Journal of Human Genetics, 31(8):887–894, March 2023. URL: http://dx.doi.org/10.1038/s41431-023-01327-7, doi:10.1038/s41431-023-01327-7. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41431-023-01327-7)

[5. (Sarangdhar2023Human) Mayuresh Anant Sarangdhar, Nicola Andina, and Ramanjaneyulu Allam. Human molecular genetics sheds light on the physiological significance of ribonuclease inhibitor (rnh1). European Journal of Human Genetics, 31(8):856–858, April 2023. URL: http://dx.doi.org/10.1038/s41431-023-01362-4, doi:10.1038/s41431-023-01362-4. This article has 2 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41431-023-01362-4)

[6. (Lee1990Modular) F S Lee and B L Vallee. Modular mutagenesis of human placental ribonuclease inhibitor, a protein with leucine-rich repeats. Proceedings of the National Academy of Sciences, 87(5):1879–1883, March 1990. URL: http://dx.doi.org/10.1073/pnas.87.5.1879, doi:10.1073/pnas.87.5.1879. This article has 21 citations.](https://doi.org/10.1073/pnas.87.5.1879)

[7. (Bombaci2022LRRprotein) Giuseppe Bombaci, Mayuresh Anant Sarangdhar, Nicola Andina, Aubry Tardivel, Eric Chi-Wang Yu, Gillian M Mackie, Matthew Pugh, Vedat Burak Ozan, Yara Banz, Thibaud Spinetti, Cedric Hirzel, Esther Youd, Joerg C Schefold, Graham Taylor, Amiq Gazdhar, Nicolas Bonadies, Anne Angelillo-Scherrer, Pascal Schneider, Kendle M Maslowski, and Ramanjaneyulu Allam. Lrr-protein rnh1 dampens the inflammasome activation and is associated with covid-19 severity. Life Science Alliance, 5(6):e202101226, March 2022. URL: http://dx.doi.org/10.26508/lsa.202101226, doi:10.26508/lsa.202101226. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.26508/lsa.202101226)